Brett W Sperry1, Balaji K Tamarappoo1, Jorge D Oldan2, Omair Javed1, Daniel A Culver3, Richard Brunken4, Manuel D Cerqueira4, Rory Hachamovitch5. 1. Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio. 2. Department of Radiology, University of North Carolina, Chapel Hill, North Carolina. 3. Department of Pulmonary Medicine, Cleveland Clinic Foundation, Cleveland, Ohio. 4. Department of Nuclear Medicine, Imaging Institute, Cleveland Clinic Foundation, Cleveland, Ohio. 5. Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio. Electronic address: hachamr@ccf.org.
Abstract
OBJECTIVES: This study sought to evaluate the incremental value of quantifying the extent and severity of myocardial perfusion and 18F-labeled fluorodeoxyglucose (FDG) abnormalities in predicting adverse outcomes among patients with suspicion for cardiac sarcoidosis (CS). BACKGROUND: Positron emission tomography (PET) with FDG is a key component of the noninvasive assessment of patients with suspected CS. However, the optimal method for image interpretation has not been defined. METHODS: A retrospective analysis was performed of 203 patients who underwent perfusion and FDG-PET imaging to evaluate for CS. Imaging findings were scored by conventional 3-category methods (normal perfusion and metabolism, abnormal perfusion or metabolism, abnormal perfusion and metabolism) and by summed scores using the 17-segment model to represent extent and severity of disease. Heterogeneity of metabolism was quantified using the coefficient of variation (SD divided by the mean) of FDG uptake. Multivariable Cox models were developed to assess associations between imaging findings and adverse events (death, heart transplant, or ventricular arrhythmia requiring defibrillation). RESULTS: The indication for FDG-PET was ventricular arrhythmia in 69 (34%), heart block in 16 (8%), cardiomyopathy in 54 (27%), and other indications in 64 (32%). There were 63 patients who developed adverse events over a mean follow-up of 1.8 years. After robust adjustment, only the summed score in segments with a perfusion-metabolism mismatch and the coefficient of variation were important prognostically (p = 0.029 and p = 0.041, respectively). CONCLUSIONS: Quantitative measures of extent and severity of perfusion-metabolism mismatch and coefficient of variation of FDG uptake provide an incremental prognostic advantage in patients undergoing FDG-PET for CS. These results support the use of a more detailed analysis of imaging findings, as is conventional in coronary artery disease.
OBJECTIVES: This study sought to evaluate the incremental value of quantifying the extent and severity of myocardial perfusion and 18F-labeled fluorodeoxyglucose (FDG) abnormalities in predicting adverse outcomes among patients with suspicion for cardiac sarcoidosis (CS). BACKGROUND: Positron emission tomography (PET) with FDG is a key component of the noninvasive assessment of patients with suspected CS. However, the optimal method for image interpretation has not been defined. METHODS: A retrospective analysis was performed of 203 patients who underwent perfusion and FDG-PET imaging to evaluate for CS. Imaging findings were scored by conventional 3-category methods (normal perfusion and metabolism, abnormal perfusion or metabolism, abnormal perfusion and metabolism) and by summed scores using the 17-segment model to represent extent and severity of disease. Heterogeneity of metabolism was quantified using the coefficient of variation (SD divided by the mean) of FDG uptake. Multivariable Cox models were developed to assess associations between imaging findings and adverse events (death, heart transplant, or ventricular arrhythmia requiring defibrillation). RESULTS: The indication for FDG-PET was ventricular arrhythmia in 69 (34%), heart block in 16 (8%), cardiomyopathy in 54 (27%), and other indications in 64 (32%). There were 63 patients who developed adverse events over a mean follow-up of 1.8 years. After robust adjustment, only the summed score in segments with a perfusion-metabolism mismatch and the coefficient of variation were important prognostically (p = 0.029 and p = 0.041, respectively). CONCLUSIONS: Quantitative measures of extent and severity of perfusion-metabolism mismatch and coefficient of variation of FDG uptake provide an incremental prognostic advantage in patients undergoing FDG-PET for CS. These results support the use of a more detailed analysis of imaging findings, as is conventional in coronary artery disease.
Authors: David Birnie; Rob S B Beanlands; Pablo Nery; Shawn D Aaron; Daniel A Culver; Robert A DeKemp; Lorne Gula; Andrew Ha; Jeffery S Healey; Yuko Inoue; Mark A Judson; Daniel Juneau; Kengo Kusano; Russell Quinn; Lena Rivard; Mustafa Toma; Amanda Varnava; George Wells; Melissa Wickremasinghe; Jordana Kron Journal: Am Heart J Date: 2019-10-20 Impact factor: 4.749
Authors: Lynda E Rosenfeld; Mina K Chung; Clifford V Harding; Paolo Spagnolo; Johan Grunewald; Jason Appelbaum; William H Sauer; Daniel A Culver; Jose A Joglar; Ben A Lin; Christine L Jellis; Timm-Michael Dickfeld; Deborah H Kwon; Edward J Miller; Paul C Cremer; Frank Bogun; Jordana Kron; Ashley Bock; Davendra Mehta; Paul Leis; Konstantinos C Siontis; Elizabeth S Kaufman; Thomas Crawford; Peter Zimetbaum; Edwin T Zishiri; Jagmeet P Singh; Kenneth A Ellenbogen; Jonathan Chrispin; Syed Quadri; Logan L Vincent; Kristen K Patton; Steven Kalbfleish; Thomas D Callahan; Francis Murgatroyd; Marc A Judson; David Birnie; David R Okada; Christopher Maulion; Pavan Bhat; Lavanya Bellumkonda; Ron Blankstein; Richard K Cheng; Maryjane A Farr; Jerry D Estep Journal: Circ Arrhythm Electrophysiol Date: 2021-02-16
Authors: Piotr J Slomka; Jonathan B Moody; Robert J H Miller; Jennifer M Renaud; Edward P Ficaro; Ernest V Garcia Journal: J Nucl Cardiol Date: 2020-10-16 Impact factor: 5.952